Free Trial
NASDAQ:FHTX

Foghorn Therapeutics Q2 2025 Earnings Results & Report

Foghorn Therapeutics logo
$2.07 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$2.06 0.00 (-0.24%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Foghorn Therapeutics beat analyst earnings expectations but missed on revenue in its Q2 2025 results, released August 5, 2025. The company reported EPS of -$0.28 versus the -$0.31 consensus estimate, while revenue of $7.56 million fell short of the $7.62 million estimate by $60.00 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Foghorn Therapeutics EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Foghorn Therapeutics Revenue Results

Actual Revenue
$7.56 million
Expected Revenue
$7.62 million
Beat/Miss
Missed by -$60.00 thousand
YoY Revenue Growth
N/A

Foghorn Therapeutics Q2 2025 Earnings FAQ

Foghorn Therapeutics (NASDAQ:FHTX) reported earnings of -$0.28 per share for Q2 2025, beating the consensus estimate of -$0.31. The report was announced on Tuesday, August 5, 2025.

Foghorn Therapeutics reported revenue of $7.56 million for Q2 2025, against a consensus estimate of $7.62 million.

Foghorn Therapeutics Earnings Headlines

HC Wainwright Analysts Increase Earnings Estimates for FHTX
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Foghorn Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Foghorn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Foghorn Therapeutics and other key companies, straight to your email.

About Foghorn Therapeutics

Foghorn Therapeutics (NASDAQ:FHTX) is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted.

The company’s Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines.

Founded in 2015 and based in Cambridge, Massachusetts, Foghorn has pursued research collaborations with other pharmaceutical companies, including Eli Lilly. Adrian Gottschalk has served as the company’s chief executive officer.

View Foghorn Therapeutics Profile